Physician profile
Michael Forehand
NPI 1730133521
$2,021.11
in general payments reported to CMS, 2019-2025
15 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $471 · 2023: $218 · 2024: $1,208 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.97 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $355.64 | 2022-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $301.06 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $146.53 | 2023-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Austedo Xr |
| Alkermes, INC. | $124.26 | 2025 | Lybalvi |
| Tris Pharma INC | $108.85 | 2024 | Quillichew Er, Quillivant, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $104.95 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $87.46 | 2024 | Trintellix |
| Lundbeck LLC | $69.72 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $51.17 | 2023-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.82 | 2024 | Caplyta |
| Genentech USA, INC. | $25.34 | 2022 | |
| Novo Nordisk INC | $15.37 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Forehand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.